If you can't tolerate lisinopril, amlodipine, metoprolol, losartan or HCTZ, will Tryvio work? What are the pros & cons of this BP drug?

Idorsia is making moves to stretch its cash reserves further. The Swiss drugmaker said it is narrowing its operations with 270 positions at risk of elimination. The potential layoffs will most likely impact its R ...

The drug was approved last year for patients with hypertension currently not controlled on other BP-lowering agents.

Idorsia announces 270 potential layoffs, primarily affecting R&D and headquarters support functions. The company is negotiating to out-license blood pressure drug Tryvio, including a $35 million exclu...

Srishti Gupta exits as Idorsia CEO after brief tenure, causing 13% stock drop. Jean-Paul Clozel initiates new CEO search. FDA removes REMS requirement for blood pressure drug Tryvio.

Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and...

Idorsia announces 270 potential layoffs, primarily affecting R&D and headquarters support functions. The company is negotiating to out-license blood pressure drug Tryvio, including a $35 million exclu...

(MedPage Today) -- The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The once-daily oral medication is...

TRYVIO and JERAYGO represent a revolutionary advancement in managing resistant hypertension, offering new hope for patients unresponsive to traditional therapies.

Idorsias Kooperation mit Stanford und Duke beschleunigt den US-Markteintritt von Bluthochdruckmittel Tryvio und treibt die Aktie um über 6 Prozent nach oben.

Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other medications.…

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO, approved by the FDA in March 2024 and commercially available since October 2024, targets systemic hypertension in adults not adequately controlled on other drugs. LAS VEGAS, April 17, 2025 …

Plus, news about Vincerx and Cytora: Idorsia’s Tryvio gets safety restriction removed: Patients taking Idorsia’s blood pressure pill no longer have to take part in a drug safety program. The FDA ...

With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate licensing deal with Viatris.

Idorsia’s plan to hand over the global rights to its blood pressure drug Tryvio has ended in disappointment after a deal announced in November fell through. The Swiss drugmaker said Thursday ...

Plus, news about Pyxis, Epitopea and Genevant: Idorsia’s deal for blood pressure drug hits snag: The Swiss company said negotiations with an unnamed party for

Idorsia’s plans to sell its hypertension drug Tryvio have faced a speedbump, even as the biotech ploughs ahead with around 250 layoffs.